Nowadays, routine definition of molecular subtypes of BC is based on immunohistochemical surrogates, derived from the assessment of the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and on the quantification of the proliferation index. This evidence concerns the gene ESR1 and breast cancer.